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Abstract
Objectives: Mipomersen, an antisense oligonucleotide targeting apolipoprotein B synthesis, significantly reduces LDL-C and
other atherogenic lipoproteins in familial hypercholesterolemia when added to ongoing maximally tolerated lipid-lowering
therapy. Safety and efficacy of mipomersen in patients with severe hypercholesterolemia was evaluated.
Methods and Results: Randomized, double-blind, placebo-controlled, multicenter trial. Patients (n = 58) were $18 years
with LDL-C $7.8 mmol/L or LDL-C $5.1 mmol/L plus CHD disease, on maximally tolerated lipid-lowering therapy that
excluded apheresis. Weekly subcutaneous injections of mipomersen 200 mg (n = 39) or placebo (n = 19) were added to
lipid-lowering therapy for 26 weeks. Main outcome: percent reduction in LDL-C from baseline to 2 weeks after the last dose
of treatment. Mipomersen (n = 27) reduced LDL-C by 36%, from a baseline of 7.2 mmol/L, for a mean absolute reduction of
2.6 mmol/L. Conversely, mean LDL-C increased 13% in placebo (n = 18) from a baseline of 6.5 mmol/L (mipomersen vs
placebo p,0.001). Mipomersen produced statistically significant (p,0.001) reductions in apolipoprotein B and
lipoprotein(a), with no change in high-density lipoprotein cholesterol. Mild-to-moderate injection site reactions were the
most frequently reported adverse events with mipomersen. Mild-to-moderate flu-like symptoms were reported more often
with mipomersen. Alanine transaminase increase, aspartate transaminase increase, and hepatic steatosis occurred in 21%,
13% and 13% of mipomersen treated patients, respectively. Adverse events by category for the placebo and mipomersen
groups respectively were: total adverse events, 16(84.2%), 39(100%); serious adverse events, 0(0%), 6(15.4%);
discontinuations due to adverse events, 1(5.3%), 8(20.5%) and cardiac adverse events, 1(5.3%), 5(12.8%).
Conclusion: Mipomersen significantly reduced LDL-C, apolipoprotein B, total cholesterol and non-HDL-cholesterol, and
lipoprotein(a). Mounting evidence suggests it may be a potential pharmacologic option for lowering LDL-C in patients with
severe hypercholesterolemia not adequately controlled using existing therapies. Future studies will explore alternative
dosing schedules aimed at minimizing side effects.
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Introduction
Familial hypercholesterolemia (FH), an autosomal dominant
disorder characterized by elevated plasma levels of low-density
lipoprotein cholesterol (LDL-C) is most commonly caused by a
mutation in the LDL receptor gene. [1] The risk of a coronary
event before age 65 is 85% in men and 50% in women with
untreated heterozygous FH. [2] Although high dose statin therapy
in combination with other lipid-lowering agents is effective in these
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patients, a small percentage have refractory severe hypercholes-
terolemia.[3–6] In small non-randomized studies LDL-apheresis
reduces cardiac events and improves overall survival; however, it
has limited availability, generally requires a fistula, and costs over
J2500 for biweekly sessions. [5,7] In the US, fewer than 200 of the
6000 qualified persons with severe hypercholesterolemia receive
apheresis. [7] Agents capable of lowering LDL-C via novel
mechanisms of action are needed.
In previous trials, weekly subcutaneous (SC) injections of
mipomersen 200 mg reduced LDL-C by 25% and 28% in
patients with FH when added to existing treatments. [8,9]
Mipomersen is an antisense oligonucleotide inhibitor of apolipo-
protein B (Apo B) synthesis. It binds to messenger RNA encoding
apolipoprotein B preventing its synthesis and secretion of Apo B
containing atherogenic lipoproteins. [8,10] This study assessed the
safety and efficacy of mipomersen 200 mg per week in patients
with severe hypercholesterolemia receiving maximally tolerated
lipid-lowering therapy that excluded apheresis and found treat-
ment to significantly lower atherogenic lipoproteins.
Methods
Ethics Statement
This randomized, double-blind, placebo-controlled, multi-cen-
ter, Phase 3 trial was undertaken between January 27, 2009 and
October 14, 2010 and performed in accordance with the
Declaration of Helsinki with approval by each Institutional
Review Board. This multicenter study included 26 study locations;
the names of Institutions and their corresponding institutional
review boards/independent ethics committees are listed in the
supplemental material. At screening and after adequate explana-
tion of the aims, methods, anticipated benefits, and potential
hazards of the study, all patients provided written informed
consent.
Study Design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. Adults patients with severe hypercholesterolemia
defined as an LDL-C $5?1 mmol/L with known CHD or an
LDL-C $7?8 mmol/L in the absence of known CHD provided
written informed consent. [11] Patients were on a stable low fat
diet, at a stable weight, on maximally tolerated lipid-lowering
therapy, met LDL-apheresis criteria but apheresis was prohibit-
ed.[12–14] Exclusions included significant cardiovascular or
cerebrovascular events within 24 weeks of screening, congestive
heart failure, type I diabetes, poorly controlled type II diabetes,
hypertension, secondary hyperlipidemia predisposition, or a
history of significant renal or hepatic disease.
After 4-weeks screening, eligible patients were randomized to 26
weeks of self-administered mipomersen 200 mg per week or
placebo, which consisted of 9 mg of sodium chloride, 0.004 mg of
riboflavin, filled to sufficient quantity with 1 mL water for
injection. The placebo was similar to active drug in appearance
and administration. Permuted block randomization (blocks of size
3) was used to allocate patients to treatment in a 2:1 ratio. There
were no stratification factors used; 36 sites screened patients and
26 sites enrolled and randomized at least 1 patient. Patients were
enrolled by the principal investigator at each study site after which
the investigator or study coordinator called an interactive voice
response system that provided blinded medication kits coded to
assure that all clinical, medical, and pharmacy personnel, as well
as the patient, remained blinded to treatment allocation. All
Figure 1. Patient Disposition – Consort Diagram.
doi:10.1371/journal.pone.0049006.g001
Mipomersen Lowers LDL-C, Apo(B), and Lipoproteins
PLOS ONE | www.plosone.org 2 November 2012 | Volume 7 | Issue 11 | e49006
clinical operations, data management, and statistical personnel
also remained blinded until the database was locked. Patients
underwent baseline liver and spleen magnetic resonance (MRI) or
computed tomography with follow-up only in patients experienc-
ing an ALT $3 X ULN on 2 consecutive results one week apart.
MRI of hepatic fat content was performed by an assessor masked
to treatment. [15].
Total cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C) and triglycerides (TG) were measured by enzymatic
colorimetry. Lipoprotein(a) [Lp(a)] was measured by a standard-
ized isoform independent assay. Rate nephelometry assessed
apolipoprotein B–100 and apolipoprotein A1. [16,17] By protocol,
discontinuation was required if alanine transaminase (ALT) or
aspartate aminotransferase (AST) levels were: $8 X ULN, $5 X
ULN on 2 consecutive weeks, or $3 X ULN in conjunction with
Table 1. Baseline Characteristics.
Placebo Mipomersen Total
(N =19) (N =39) (N =58)
Age (years) Mean (SD) 47?9 (13?5) 51?8 (14?3) 50?5 (14?0)
[Min, Max] [18, 66] [21, 77] [18, 77]
Gender n (%)
Male 7 (36?8) 18 (46?2) 25 (43?1)
Female 12 (63?2) 21 (53?8) 33 (56?9)
Race n (%)
White 16 (84?2) 33 (84?6) 49 (84?5)
Black 1 (5?3) 2 (5?1) 3 (5?2)
Asian 0 (0?0) 1 (2?6) 1 (1?7)
Multiple 2 (10?5) 1 (2?6) 3 (5?2)
Other 0 (0?0) 2 (5?1) 2 (3?4)
BMI (kg/m2)
Mean (SD) 29?9 (4?10) 28?4 (5?35) 28?9 (4?98)
[Min, Max] [22?8, 36?9] [19?4, 39?8] [19?4, 39?8]
Waist/hip ratio
Mean (SD) 0?94 (0?06) 0?92 (0?09) 0?93 (0?08)
[Min, Max] [0?8, 1?0] [0?7, 1?1] [0?7, 1?1]
Current smoker n (%) 5 (26?3) 4 (10?3) 9 (15?5)
Alcohol use n (%)
Current 7 (36?8) 27 (69?2) 34 (58?6)
Non-current 4 (21?1) 5 (12?8) 9 (15?5)
Never 8 (42?1) 7 (17?9) 15 (25?9)
Metabolic syndrome, n (%)a
No 10 (52?6) 25 (64?1) 35 (60?3)
Yes 9 (47?4) 14 (35?9) 23 (39?7)
History of:
Angina 5 (26?3) 11 (28?2) 16 (27?6)
Myocardial infarction 4 (21?1) 8 (20?5) 12 (20?7)
Coronary Artery Bypass Graft 6 (31?6) 12 (30?8) 18(31?0)
Percutaneous Coronary Intervention 2 (10?5) 4 (10?3) 6 (10?3)
Coronary Artery Disease without event 5 (26?3) 11 (28?2) 16 (27?6)
Peripheral Artery Disease 2 (10?5) 1 (2?6) 3 (5?2)
Abdominal Aortic Aneurysm 0 (0?0) 1 (2?6) 1 (1?7)
Carotid Disease 5 (26?3) 6 (15?4) 11 (19?0)
Coronary Heart Disease or other Atherosclerotic disease (clinical diagnosis) 15 (78?9) 31 (79?5) 46 (79?3)
Lipid Lowering Medications, n (%) 19 (100?0) 39 (100?0) 58 (100?0)
Maximal statin 8 (42?1) 16 (41?0) 24 (41?4)
Statin with ezetimibe 11 (57?9) 20 (51?3) 31 (53?4)
Abbreviations: BMI, body mass index; Max, maximum; Min, minimum; SD, standard deviation.
aMetabolic syndrome determined according to the American Heart Association and the National Heart, Lung, and Blood Institute definition.
doi:10.1371/journal.pone.0049006.t001
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total bilirubin .1?5 X ULN or international normalized ratio
.1?5.
Primary endpoint was percent change in LDL-C from baseline
to 2 weeks after last dose. For study completers this was week 28.
Secondary endpoints included percent change from baseline in
apolipoprotein B, non-high-density lipoprotein cholesterol (non-
HDL-C), and TC. Other endpoints included changes from
baseline in TG, Lp(a), very low-density lipoprotein cholesterol,
apolipoprotein A1, high-density lipoprotein cholesterol (HDL-C),
and LDL/HDL ratio.
Statistical Analysis
Based on prior clinical experience with mipomersen the
standard deviation of the percent change in LDL-C was estimated
at 22%. With a 2:1 mipomersen to placebo randomization, the
study had to have at least an 80% power to detect a 20%
difference between the 2 treatment groups with 45 patients using a
2-sided alpha of 5%. Efficacy comparisons employed two-sample
t-test or the Wilcoxon rank sum test, as appropriate, on the
intention-to-treat population and per-protocol population. Statis-
tical significance was defined as p#0?05 and type I error was
controlled for the primary and secondary endpoints using a
sequential inferential approach. All randomized patients who
received at least 1 injection of study drug and had a valid baseline
with at least 1 post-baseline LDL-C measurement were analyzed
for efficacy. Several sensitivity analyses were performed on the
primary efficacy endpoint. One analysis was run using the LDL-C
value closest to week 28 for each patient, regardless of when
treatment ended. In addition, a post-hoc mixed model for
repeated measures analysis was conducted including the fixed,
categorical effects of treatment, visit, and treatment-by-visit
interaction, as well as the continuous, fixed covariate of baseline
LDL-C. All randomized patients who received at least 1 injection
of study drug were evaluated for safety.
Protocol Deviations
In this study 49 patients (35 mipomersen; 14 placebo); had at
least 1 protocol deviation; not all protocol deviations resulted in
exclusion from analysis. Sixteen patients (2 in the placebo group
and 14 in the mipomersen group) were excluded from the per-
protocol population: 7 (all in the mipomersen group) due to
inadequate time on study drug; 6 (2 in the placebo group and 4 in
the mipomersen group) due to a large LDL-C difference between
screening and baseline indicating that LDL-C levels were not
stable prior to treatment; and 5 (all in the mipomersen group) due
to prescribed medication changes.
The study sponsor, with critical contributions from principal
investigators, designed the trial in accordance with the principles
of Good Clinical Practice. The sponsor was responsible for data
collection and statistical analysis; authors were involved in analysis
and interpretation. The corresponding author had full access to
data and was responsible for manuscript preparation. Trial
Registration: clinicaltrials.gov–NCT00794664. http://
clinicaltrials.gov/ct2/show/NCT00794664.
Results
Fifty-eight patients were randomized; 45 patients completed 26
weeks from January 27, 2009 to October 14, 2010 (Figure 1). The
most common reason for discontinuation was adverse events
(AEs). Most patients (79?3%) had a medical history of CHD or
other clinical atherosclerotic disease; 40% had metabolic syn-
drome. Treatment groups were similar, except for tobacco and
alcohol use (Table 1).
All 58 treated patients were evaluated for safety. One placebo
patient had no post-baseline LDL-C measurements and so 57
patients were evaluated in the intent-to-treat population. Of these,
41 patients (25 mipomersen; 16 placebo) were evaluated in the
per-protocol population.
Despite maximally tolerated lipid-lowering therapy, with 41%
of patients at maximal statin dose) the mean baseline LDL-C and
other lipid levels were elevated (Table 2). Lp(a), commonly
elevated in FH, was also high. [18] Niacin was a concomitant
medication in 2 (5.1%) mipomersen patients, and 1 (5.3%) placebo
patient. The mean percent change in LDL-C of236% (95% CI, –
51?3, 215?3) in mipomersen patients was statistically significant
(p,.001) compared to the mean percent change of 12?5% (95%
CI, –10?8 to 35?8) in placebo patients (Figure 2). This corresponds
to a mean absolute change of22?62 mmol/L (from 7?15 mmol/L
to 4?53 mmol/L) and 0?38 mmol/L (from 6?46 mmol/L to
6?84 mmol/L) in mipomersen and placebo patients, respectively.
Changes in apolipoprotein B, TC, non-HDL-C, and Lp(a)
mirrored these findings (Table 2, Figure 3). Sensitivity analyses
on the primary endpoint produced similar results to the primary
analysis.
A .15% decrease in LDL-C was seen in 79% of mipomersen
patients compared with 17% of placebo patients. Moreover, 10
(25?6%) mipomersen patients had a .50% decrease in LDL-C, 6
(15?4%) achieved a target LDL-C level of ,2?6 mmol/L, and 3
(7?7%) achieved LDL-C levels ,1?8 mmol/L; no placebo patients
experienced LDL-C reductions of this magnitude. There was a
more robust LDL-C reduction in females than males (mean
reduction 44% vs. 27%) in the mipomersen group; nonetheless,
the 27% reduction in men was statistically significant and clinically
meaningful.
Statins, ezetimibe, and bile acid sequestrants have limited
impact on Lp(a). [9,19] Mipomersen resulted in a 33% (95% CI,
243?3, 222?0) reduction in Lp(a) compared with a 1?5% (95%
CI, –14?3, 11?3) reduction with placebo (Table 2, Figure 3).
Figure 2. Mean Absolute Reduction in LDL-C (value closest to 2
weeks after the end of study treatment).
doi:10.1371/journal.pone.0049006.g002
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At study end, 67% of placebo patients still met LDL-apheresis
criteria versus 28% of mipomersen patients. [9,17] Among
patients with CHD or other atherosclerotic diseases at baseline,
79% of placebo patients and 32% of mipomersen patients still met
LDL-apheresis criteria (LDL-C $5.1 mmol/L). Among patients
without CHD or other atherosclerotic diseases at baseline, 12% of
placebo patients and 25% of mipomersen patients still met LDL-
apheresis criteria (LDL-C $7.8 mmol/L).
All mipomersen patients experienced at least one AE (Table 3).
The most common AEs were mild-to-moderate injection site
reactions (ISRs) representing 79% of mipomersen AEs (pain, 59%;
erythema, 56%; pruritus, 33%) generally abating within 2 to 3
days. One patient had severe injection site erythema leading to
early discontinuation. Mild or moderate flu-like symptoms (FLS)
occurred in 46% of mipomersen and 21% of placebo patients. The
onset of FLS was generally seen early in treatment; 1 patient
withdrew after 1 dose of mipomersen due to this event. Repeated
administration of mipomersen did not result in worsening of local
ISRs or FLS, which did not occur with every injection.
During treatment 6 mipomersen and 0 placebo patients
reported a serious AE (SAE); after treatment, 5 mipomersen and
1 placebo patient reported a SAE. Two patients experienced SAEs
Figure 3. Mean Percent Change from Baseline to Week 28. Error bars indicate 95% CI. Placebo (n = 18); mipomersen 200 mg weekly (n = 39).
(A) Low-density lipoprotein cholesterol (LDL-C) (B) Apolipoprotein B (Apo B) (C) Lipoprotein(a) (Lp(a)) (D) Non-high density lipoprotein cholesterol
(non-HDL-C) (E) Total Cholesterol.
doi:10.1371/journal.pone.0049006.g003
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considered drug-related (ALT increased, AST increased, and
hepatic steatosis in one patient and cerebrovascular accident,
angina pectoris, with Prinzmetal angina, considered possibly drug-
related, in another). Nine patients (8 from the mipomersen group)
withdrew due to AEs. Although 6 patients withdrew from the
mipomersen group for transaminase elevation, only two patients
met protocol-defined stopping rules (1 patient with ALT .8 X
ULN and 1 patient with ALT $3X ULN with the appearance/
worsening of fatigue, aches, and right upper quadrant pain or
tenderness. One patient withdrew due to moderate FLS and 1
patient due to severe ISR. One patient in the placebo group
experienced headache, fatigue, and restless leg syndrome resulting
Table 3. On-Treatment Adverse Events Reported in at Least 10% of Mipomersen Patients.
Placebo (N =19) Mipomersen (N =39)
Adverse Events Events (#) Patients n (%) Events (#) Patients n (%)
All events 69 16 (84?2) 1114 39 (100?0)
Injection site reaction 38 6 (31?6) 877 35 (89?7)
Flu-like symptoms (influenza-like illness, influenza, pyrexia, chills,
myalgia, arthralgia, malaise, fatigue)
5 4 (21?1) 59 18 (46?2)
Alanine aminotransferase increased 0 0 (0) 8 8 (20?5)
Aspartate aminotransferase increased 0 0 (0) 5 5 (12?8))
Nausea 0 0 (0) 7 5 (12?8)
Hepatic steatosis 0 0 (0) 5 5 (12?8)
Nasopharyngitis 1 1 (5?3) 8 4 (10?3)
Cardiac events 1 1 (5?3) 12 5 (12?8)
Acute myocardial infarctiona, b 1 1 (2?6)
Angina pectorisc 1 1 (5?3) 4 2 (5?1)
Angina unstableb 1 1 (2?6)
Cardiac failureb 1 1 (2?6)
Coronary artery diseaseb 2 1 (2?6)
Prinzmetal anginad 2 1 (2?6)
Supraventricular extrasystolesb 1 1 (2.6)
aThis patient also had another acute myocardial infarction occurring during post-treatment follow-up, which was fatal.
bEvents not related to study drug in the opinion of the investigator.
c3 of 4 events of angina pectoris in the mipomersen group were considered drug-related. The 4th event and the event in the placebo group were considered not drug-
related.
dConsidered possibly drug-related.
doi:10.1371/journal.pone.0049006.t003
Table 4. Laboratory Abnormalities of Interest.
Placebo (N =19) Mipomersen (N =39)
Laboratory Abnormalitiesa n (%) n (%)
ALT elevations
.ULN and ,2 X ULN 6 (31?6) 9 (23?1)
$2 X ULN and ,3 X ULN 1 (5?3) 9 (23?1)
$3 X ULN and ,10 X ULN 0 (0) 11 (28?2)
$10 X ULN 0 (0) 1 (2?6)
Proteinuria (dipstick)
$1+ 3 (15?8) 12 (30?8)
$2+ 1 (5?3) 7 (17?9)
Serum creatinine
1.3x . baseline 4 (21?1) 8 (20?5)
Women, n = 12, 21b $0?2 mg/dL above baselinec 1 (8?3) 6 (28?6)
Abbreviations: ALT, alanine aminotransferase; ULN, upper limit of normal range.
aNot all laboratory abnormalities were reported as AEs.
bThe numbers after ‘n = ’ are the total numbers of male/female patients in the placebo group and in the mipomersen group, respectively.
cPercentages are calculated out of the total number of treated male or female patients, respectively, for the particular treatment group.
doi:10.1371/journal.pone.0049006.t004
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in early termination. On-treatment cardiac events are shown in
Table 3. Of these events 2 patients had events considered drug-
related or possibly drug-related–Prinzmetal angina (1 patient with
2 events) and angina pectoris (2 patients with 3 events). Two
patients had non-drug related events occurring in the follow-up
period: one had supraventricular tachycardia the other acute
myocardial infarction.
Table 4 lists laboratory abnormalities. The incidence of serum
creatinine increases .1?3 X baseline were comparable between
the treatment groups. In most cases (5/8 mipomersen; 3/4
placebo), elevations in serum creatinine did not occur in the same
patients experiencing proteinuria. Beta-2 microglobulin assessed
tubular effects; there was no notable difference between groups.
Twelve patients (31%) in the mipomersen group and no placebo-
treated patients had ALT and/or AST $3 X ULN. No patients
had a significant increase in bilirubin or other abnormalities in
liver function. For-cause post-baseline MRIs in 7 of the 12
mipomersen patients revealed increased liver fat content (Table 5);
3 had steatosis. Patients with increased liver fat also demonstrated
reductions in LDL-C considerably larger than the group mean
(range: 244.1% to 277.4%). Six of the 7 patients had a follow-up
MRI after treatment ended; liver fat content fell significantly in 5
patients.
Although anti-mipomersen antibodies (titer = 100 to 12,800)
were detected in 14/39 mipomersen-treated patients, efficacy was
not impacted (mean LDL-C reduction of 34%). One patient had
2+ proteinuria at screening and was discontinued due to AEs of
nausea, ALT elevation, and liver tenderness. For-cause MRI also
revealed increased liver fat (patient 4, Table 5). Mipomersen had
no adverse impact on muscle function, platelet count, blood sugar,
or blood pressure.
Discussion
Clinical trials demonstrate significant reductions in both cardiac
events and mortality with statins in high risk populations.[20–22]
On a background of maximally tolerated lipid-lowering therapy,
mipomersen 200 mg weekly lowered LDL-C an additional 36%
(absolute mean reduction of 2.61 mmol/L) in patients with severe
hypercholesterolemia. Females had a greater LDL-C lowering
compared with males however, both groups had statistically
significant and clinically meaningful reductions. Significant
reductions in apolipoprotein B, non-HDL-C, and Lp(a) also
occurred.
If sustained, LDL-C reductions of this magnitude (absolute
mean reduction of 2?6 mmol/L) may reduce cardiac morbidity
and mortality. A meta-analysis of statin trials suggested that for
each 1 mmol/L reduction in LDL-C there is a corresponding 21%
to 27% reduction in major vascular events, a 19% to 28%
reduction in CHD-mortality, and a 12% to 16% reduction in all-
cause mortality. [22,23] Unlike statins, mipomersen also reduced
Lp(a), a known independent predictor of CHD risk, and may result
in even greater cardiovascular risk reduction than predicted from
the aforementioned trials. [8,9,18,24,25].
The most common AEs with a higher incidence in the
mipomersen group included ISRs and FLS. While neither is life-
threatening, both can influence a patient’s willingness to remain
on treatment. A large, currently enrolling clinical trial
(NCT01475825) is exploring lower, more frequent dosing as a
means to minimize both ISR and FLS.
In addition to the liver, mipomersen localized in the kidneys.
[26] An increase in proteinuria and serum creatinine was noted in
some mipomersen treated patients. Although the patients experi-
encing an increase in creatinine were not typically the patients
who developed proteinuria. Cardiac events occurred more
frequently in the mipomersen group. Because several previous
mipomersen studies did not note an increase in cardiac events, it is
possible that this represents a chance occurrence. Larger, long-
term studies are required to determine the significance of both
kidney function changes and cardiac events. In this and previous
studies mipomersen had no adverse effect on blood pressure. [8].
A critical long-term safety concern is the potential for hepatic
steatosis due to the accumulation of TG following inhibition of
Apo B synthesis. It is reassuring that persons with familial
hypobetalipoproteinemia, a genetic disorder characterized by
reduced Apo B synthesis and life-long depressed LDL-C, enjoy a
reduced risk of cardiac disease and a concomitant increase in
lifespan despite significant hepatic fat. [27,28] Although all
commonly used lipid-lowering agents can increase ALT and
AST, these agents rarely cause clinically significant liver injury.
Table 5. Liver Fat Content, Fasting Levels of Alanine Aminotransferase, and Percent Change in LDL-C in Patients with Post-Baseline
For-Cause Magnetic Resonance Imaging Assessments.
Patient No.a Liver Fat Content Spectral Model Fat Fraction (%) Fasting ALT Levels (U/L)
LDL-C at Primary Efficacy
Timepoint (% Change from
Baseline)
Baseline
MRI 2 (Days Post
Last Dose)
MRI 3 (Days Post
Last Dose) Baseline Week 21 Week 50
1b 10?5 19?9 (2) 38?2 (186) 27 147 55 254?3
2 17?6 38?1 (43) NA 32 108 24 289?5
3 0?8 23?0 (21) 1?0 (387) 22 117 25 247?8
4 5?7 31?6 (14) 15?2 (239) 37 199 42 249?9
5 7?2 46?7 (22) 12?7 (261) 30 177c 85 277?4
6 20?9 12?1 (32) 1?9 (291) 106 268c 33 249?1
7 2?9 23?3 (242) 0 (217) 44 114 35 252?8
Abbreviations: LDL-C, low-density lipoprotein cholesterol; MRI, magnetic resonance imaging; NA, not available.
aTo preserve confidentiality, the 7 patients are indicated by sequential counter numbers.
bMRI data for this patient were spleen-corrected due to violations of the MRI protocol.
cWeek 13 result shown because week 21 results were not available.
doi:10.1371/journal.pone.0049006.t005
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[29] Following discontinuation of mipomersen, ALT levels and
hepatic fat reverted toward baseline.
Study limitations include the small study size, short-term
treatment period, and liver imaging applied only for cause. This
small cohort may not be sufficient to adequately evaluate safety
concerns. An open-label extension trial (Clinicaltrials.gov:
NCT00694109; n= 141) to evaluate the long-term safety of
mipomersen is ongoing. Studies with alternate mipomersen
regimens are also currently underway (NCT: 01475825,
00794664, 00694109, 00770146, 00706849). It is hoped that
alternative dosing schedules will minimize side effects.
Mipomersen significantly lowers LDL-C and all measured Apo
B-containing lipoproteins, including Lp(a) in a population at high
risk for developing cardiac disease. These results confirm the
benefits and consistent safety profile seen with mipomersen in
various patient populations from previous trials [8,9,24,25,30,31].
This study supports the use of mipomersen as a potential
therapeutic option for patients with severe hypercholesterolemia
not adequately controlled on currently available lipid-lowering
medications. Future trials with larger patient numbers will help
establish the utility of mipomersen as a potential therapeutic
option for the treatment of patients with severe hypercholester-
olemia.
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